📣 VC round data is live. Check it out!

Lexeo Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Lexeo Therapeutics and similar public comparables like Eupraxia Pharmaceuticals, Atea Pharmaceuticals, Vanda Pharmaceuticals, PureTech Health and more.

Lexeo Therapeutics Overview

About Lexeo Therapeutics

Lexeo Therapeutics Inc is a clinical-stage genetic medicines company committed to transforming healthcare by applying pioneering science to fundamentally alter how diseases are treated. The company focuses on preclinical and clinical stage gene therapies, specifically hereditary and acquired diseases with high unmet needs, which represent its sole business segment.


Founded

2017

HQ

United States

Employees

72

Financials (LTM)

Revenue:
EBITDA: ($112M)

EV

$282M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Lexeo Therapeutics Financials

Lexeo Therapeutics reported last 12-month revenue of — and negative EBITDA of ($112M).

In the same LTM period, Lexeo Therapeutics generated ($45K) in gross profit, ($112M) in EBITDA losses, and had net loss of ($103M).

Revenue (LTM)


Lexeo Therapeutics P&L

In the most recent fiscal year, Lexeo Therapeutics reported revenue of and EBITDA of ($98M).

Lexeo Therapeutics is unprofitable as of last fiscal year, with EBITDA margin of — and net margin of —.

See analyst estimates for Lexeo Therapeutics
LTMLast FY202320242025202620272028
Gross Profit($45K)
EBITDA($112M)($98M)($64M)($96M)($98M)
Net Profit($103M)($100M)($66M)($98M)($100M)

Financial data powered by Morningstar, Inc.

Lexeo Therapeutics Stock Performance

Lexeo Therapeutics has current market cap of $455M, and enterprise value of $282M.

Market Cap Evolution


Lexeo Therapeutics' stock price is $5.80.

Lexeo Therapeutics share price increased by 1.9% in the last 30 days, and by 246.8% in the last year.

Lexeo Therapeutics has an EPS (earnings per share) of $-1.27.

See more trading valuation data for Lexeo Therapeutics
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$282M$455M6.5%1.9%-19.2%246.8%$-1.27

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Lexeo Therapeutics Valuation Multiples

Lexeo Therapeutics trades at (2.5x) EV/EBITDA.

See NTM and 2027E valuation multiples for Lexeo Therapeutics

EV / Revenue (LTM)


Lexeo Therapeutics Financial Valuation Multiples

As of May 5, 2026, Lexeo Therapeutics has market cap of $455M and EV of $282M.

Lexeo Therapeutics has a P/E ratio of (4.4x).

LTMLast FY202320242025202620272028
EV/EBITDA(2.5x)(2.9x)(4.4x)(2.9x)(2.9x)
EV/EBIT(2.6x)(2.6x)(4.1x)(2.7x)(2.6x)
EV/Gross Profitn/m
P/E(4.4x)(4.6x)(6.9x)(4.6x)(4.6x)
EV/FCF(2.7x)(2.8x)(4.7x)(3.4x)(2.8x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Lexeo Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Lexeo Therapeutics Margins & Growth Rates

See estimated margins and future growth rates for Lexeo Therapeutics

Lexeo Therapeutics Growth Rates

23/2424/2526/2727/2828/29
EBITDA Growth49%2%
EBIT Growth54%3%
Net Profit Growth48%2%
FCF Growth37%21%

Data powered by FactSet, Inc. and Morningstar, Inc.

Lexeo Therapeutics Operational KPIs

Lexeo Therapeutics' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.5M for the same period.

Access forward-looking KPIs for Lexeo Therapeutics
Last FY202620272028
Revenue per Employee$0.0M
Opex per Employee$1.5M

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Lexeo Therapeutics Competitors

Lexeo Therapeutics competitors include Eupraxia Pharmaceuticals, Atea Pharmaceuticals, Vanda Pharmaceuticals, PureTech Health, Achieve Life Sciences, Avacta Group, Climb Bio, YungShin Global Holding, Neurogene and Swedencare.

Most Lexeo Therapeutics public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Eupraxia Pharmaceuticals(10.6x)(12.7x)
Atea Pharmaceuticals(0.9x)(0.9x)
Vanda Pharmaceuticals0.9x0.9x(1.5x)
PureTech Health43.2x43.2x(3.3x)(1.4x)
Achieve Life Sciences(8.0x)
Avacta Group3076.2x166.9x(19.7x)(14.4x)
Climb Bio(5.3x)(5.0x)
YungShin Global Holding1.6x8.3x

This data is available for Pro users. Sign up to see all Lexeo Therapeutics competitors and their valuation data.

Start Free Trial

Lexeo Therapeutics Funding History

Before going public, Lexeo Therapeutics raised $185M in total equity funding, across 2 rounds.


Lexeo Therapeutics Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Sep-21Series BD1 Capital Partners; Eventide$100MLexeo Therapeutics, a New York City-based clinical-stage gene therapy company spun out of Cornell University in 2018, develops adeno-associated virus (AAV)-mediated treatments for genetic conditions, including rare cardiovascular diseases, cardiomyopathy associated with Friedreich’s ataxia (LX2006), CLN2 Batten disease (LX1004), and APOE4-associated Alzheimer’s disease (LX1001), as well as preclinical programs in the genetics of Alzheimer’s (LX1020, LX1021). The company closed a $100 million Series B financing on September 9, 2021, co-led by D1 Capital Partners and Eventide Asset Management, with participation from CAM Capital, Verition Fund Management, Laurion Capital Management, Gray’s Creek Capital Partners, and existing Series A investors including Longitude Capital, Omega Funds, Lundbeckfonden Ventures, PBM Capital, Janus Henderson Investors, Woodline Partners LP, Invus Capital, and Alexandria Venture Investments. This followed an $85 million Series A round in January 2021 co-led by Longitude Capital and Omega Funds. Proceeds from the Series B were allocated to advance the clinical-stage pipeline toward key data catalysts and expand preclinical efforts in cardiac gene therapy and Alzheimer’s genetics, aiming to establish leadership positions in these areas. CEO R. Nolan Townsend highlighted the support from long-term investors to drive growth. Dan Sundheim of D1 Capital Partners praised the company’s gene therapy expertise and pipeline, while Joy Ghosh of Eventide noted the team’s innovative approaches to rare monogenic and larger population diseases. By 2023, Lexeo had raised a total of $183.7 million since inception, including this Series B.
Jan-21Series AAlexandria Venture Investments; Alzheimer's Drug Discovery Foundation; Invus; Janus Henderson Investors; Longitude Capital; Lundbeckfonden Ventures; Omega Funds; PBM Capital Group; Woodline Partners$85MLEXEO Therapeutics is a clinical-stage gene therapy company developing AAV-based treatments for rare and non-rare monogenic diseases as well as acquired conditions. The company was founded with National Institutes of Health small business grants in early 2018 and launched publicly in January 2021 with an $85 million Series A financing led by Longitude Capital and Omega Funds, joined by Lundbeckfonden Ventures, PBM Capital, Janus Henderson Investors, Invus, Woodline Partners, the Alzheimer's Drug Discovery Foundation, and Alexandria Venture Investments. The company was established by rare disease and gene therapy industry veterans Steven Altschuler, R. Nolan Townsend, and Jay Barth, along with gene therapy pioneer Ronald Crystal, who leads the department of genetic medicine at Weill Cornell Medicine. LEXEO's comprehensive pipeline includes three clinical-stage lead programs: LX2006 for cardiomyopathy associated with Friedreich's ataxia (Phase 1 start planned for 2021), LX1004 for CLN2 Batten disease (Phase 1/2 completed), and LX1001 for APOE4-associated Alzheimer's disease (Phase 1 ongoing), alongside up to 15 potential additional AAV gene therapy programs primarily developed at Weill Cornell Medicine. Beyond clinical development, the company allocated a meaningful portion of Series A proceeds to manufacturing infrastructure, addressing a major bottleneck in gene therapy commercialization, and established headquarters in New York City to contribute to the city's life sciences ecosystem.

Lexeo Therapeutics M&A Activity

Lexeo Therapeutics has acquired 1 company to date.

Last acquisition by Lexeo Therapeutics was on July 21st 2021. Lexeo Therapeutics acquired Stelios Therapeutics for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Lexeo Therapeutics

Stelios Therapeutics
Description
Stelios Therapeutics is a San Diego-based gene therapy developer creating AAV vectors for rare inherited cardiac diseases. Originating from University of California San Diego research, the company targets conditions like hypertrophic cardiomyopathy and arrhythmogenic right ventricular cardiomyopathy. With expertise in cardiac-specific promoters and capsid engineering, Stelios advances preclinical programs toward IND-enabling studies for systemic delivery of corrective genes.
HQ CountryUnited States
HQ City
San Diego, CA
Deal Date21 Jul 2021
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Lexeo Therapeutics acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Lexeo Therapeutics

When was Lexeo Therapeutics founded?Lexeo Therapeutics was founded in 2017.
Where is Lexeo Therapeutics headquartered?Lexeo Therapeutics is headquartered in United States.
How many employees does Lexeo Therapeutics have?As of today, Lexeo Therapeutics has over 72 employees.
Who is the CEO of Lexeo Therapeutics?Lexeo Therapeutics' CEO is Richard Nolan Townsend.
Is Lexeo Therapeutics publicly listed?Yes, Lexeo Therapeutics is a public company listed on Nasdaq.
What is the stock symbol of Lexeo Therapeutics?Lexeo Therapeutics trades under LXEO ticker.
When did Lexeo Therapeutics go public?Lexeo Therapeutics went public in 2023.
Who are competitors of Lexeo Therapeutics?Lexeo Therapeutics main competitors include Eupraxia Pharmaceuticals, Atea Pharmaceuticals, Vanda Pharmaceuticals, PureTech Health, Achieve Life Sciences, Avacta Group, Climb Bio, YungShin Global Holding, Neurogene, Swedencare.
What is the current market cap of Lexeo Therapeutics?Lexeo Therapeutics' current market cap is $455M.
Is Lexeo Therapeutics profitable?No, Lexeo Therapeutics is not profitable.
What is the current EBITDA of Lexeo Therapeutics?Lexeo Therapeutics has negative EBITDA and is not profitable.
What is the current EV/EBITDA multiple of Lexeo Therapeutics?Current EBITDA multiple of Lexeo Therapeutics is (2.5x).
What is the current FCF of Lexeo Therapeutics?Lexeo Therapeutics' last 12 months FCF is ($103M).
What is the current EV/FCF multiple of Lexeo Therapeutics?Current FCF multiple of Lexeo Therapeutics is (2.7x).
How many companies Lexeo Therapeutics has acquired to date?As of May 2026, Lexeo Therapeutics has acquired 1 company.
What was the largest acquisition by Lexeo Therapeutics?None of the M&A deals Lexeo Therapeutics has completed have disclosed valuations.
What companies Lexeo Therapeutics acquired?Lexeo Therapeutics acquired Stelios Therapeutics.
In how many companies Lexeo Therapeutics has invested to date?Lexeo Therapeutics hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Lexeo Therapeutics

Lists including Lexeo Therapeutics

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial